摘要
破骨细胞作为骨代谢平衡的一端,其数量与活性与骨吸收功能密切相关。骨保护素(OPG)/核因子受体活化蛋白配体(RANKL)/核因子受体活化蛋白受体(RANK)信号通路的发现是骨代谢研究的一个新突破。这作为维持骨平衡中最重要的分子调节机制,在破骨细胞前体细胞分化成熟及骨吸收中起着关键作用,是目前抗骨质疏松药物研究的新方向。中医药治疗骨质疏松症有着不错的临床效果,但药物干预骨代谢的机理还未完全明确。本文从OPG/RANKL/RANK信号通路的角度出发,通过查阅中外相关文献,将近年来有关破骨细胞生物学研究以及中药对破骨细胞的干预作用和调控机理作一综述。
As the balance of bone metabolism,osteoclasts are closely related to the quantity and activity of bone metabolism.The discovery of osteoprotegerin (OPG)/RANKL/RANK signaling pathway is a new breakthrough in the study of bone metabolism as the key of maintaining bone balance.Important molecular regulatory mechanisms play a key role in osteoclast precursor cell differentiation and bone resorption,and are the new directions in anti-osteoporosis drug research.Traditional Chinese medicine treatment of osteoporosis has a good clinical effect,but the mechanism of drug intervention in bone metabolism is not yet completely clear.In this paper, the recent studies on osteoclast biology and interventions and mechanisms of Chinese medicine on osteoclasts from the perspective of OPG/RANKL/RANK signaling pathway are summarized through reviewing the relevant literatures both at home and abroad.
作者
张楚天
林燕萍
ZHANG Chutian;LIN Yanping(Fujian Academy of Integrative Medicine,Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian 350122,China;College of Acupuncture and Moxibustion,Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian 350122,China)
出处
《康复学报》
2018年第5期59-64,70,共7页
Rehabilitation Medicine
基金
国家自然科学基金资助项目(81574003)
福建省科技厅引导性项目(2015Y0069)
